Five things for pharma marketers to know: Thursday, October 19, 2017

The FDA approves Kite's CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence

Drugmakers begin to up media controls, in bid to clean up digital ad supply

Like its consumer-products cousins, pharma marketers are exercising more discipline over online media. Will it yield similar results?

Up to 20% of pharma brands moving digital media spend to point-of-care

Up to 20% of pharma brands moving digital media spend to point-of-care

Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.

4 Ways To Market CAR-T Therapies

4 Ways To Market CAR-T Therapies

How should marketers position this new type of cancer therapy?

Wellpepper wins Alexa Diabetes Challenge

Wellpepper wins Alexa Diabetes Challenge

The health startup's system has a foot scanner that can take photos of a patient's feet and can look for potential foot ulcers using a machine learning image classifier.



Linda Ruschau, chief client officer of PatientPoint, talks with Larry Dobrow, senior editor at MM&M, about how to better engage with HCPs. The questions and topic were created and selected by the MM&M editorial staff. The video is sponsored by PatientPoint.


Five things for pharma marketers to know: Wednesday, October 18, 2017

Five things for pharma marketers to know: Wednesday, October 18, 2017

More than half of doctors say patients make critical, racist, or sexist comments; Anthem to launch its own PBM; drugmakers face criticism for waste

Novo's experimental diabetes drug likely to compete with Trulicity

Novo's experimental diabetes drug likely to compete with Trulicity

An FDA advisory committee is scheduled to vote Wednesday on whether to approve Novo's semaglutide, which, if approved, could steal market share from Eli Lilly's Trulicity.

Five things for pharma marketers to know: Tuesday, October 17, 2017

Five things for pharma marketers to know: Tuesday, October 17, 2017

J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing

Five things for pharma marketers to know: Monday, October 16, 2017

Five things for pharma marketers to know: Monday, October 16, 2017

FDA briefing document affirms diabetes drug's efficacy; J&J debuts new tools to improve adherence; AZ says cancer drug data was falsified

IntrusiveThoughts.org takes 'approachable' approach to redesign of OCD site

IntrusiveThoughts.org takes 'approachable' approach to redesign of OCD site

Two key creators from Ready Set Rocket share how a thoughtful execution can destigmatize mental illness.

Five things for pharma marketers to know: Friday, October 13, 2017

Five things for pharma marketers to know: Friday, October 13, 2017

Outcome Health reportedly misled advertisers; FDA committee recommends gene therapy; Avanir drug is highly prescribed by docs paid by company

Muscular Dystrophy Association taps Lynn O'Connor Vos as CEO

Muscular Dystrophy Association taps Lynn O'Connor Vos as CEO

The association said it is preparing for new FDA approvals for therapies that treat central nervous system and muscular system diseases.

Five things for pharma marketers to know: Thursday, October 12, 2017

Five things for pharma marketers to know: Thursday, October 12, 2017

Merck scraps plans for cholesterol drug; oncologist describes how he tells people about his work; researchers question list of side effects in DTC ads

Nonprofits focus attention on metastatic breast cancer this October

Nonprofits focus attention on metastatic breast cancer this October

Susan G. Komen and the Breast Cancer Research Foundation are focusing on raising awareness and research money for the deadliest forms of the disease.

Five things for pharma marketers to know: Wednesday, October 11, 2017

Five things for pharma marketers to know: Wednesday, October 11, 2017

Pfizer considers sale of its consumer healthcare business; Express Scripts moves into patient benefit management; China to speed up drug approvals

Five things for pharma marketers to know: Tuesday, October 10, 2017

Five things for pharma marketers to know: Tuesday, October 10, 2017

Patients complain about positive healthcare ads; some drugmakers skirt Open Payment rules; new law requires disclosure of drug price hikes in California

Astellas turns to 'corporate branding 2.0'

Astellas turns to 'corporate branding 2.0'

The communications team, led by Jeff Winton, is again researching Astellas' reputation for an updated picture on where the campaign has gotten them so far.

Five things for pharma marketers to know: Friday, October 6, 2017

Five things for pharma marketers to know: Friday, October 6, 2017

AbbVie to pay $140 million to AndroGel patient; Trump likely to roll back birth-control mandate; patients more likely to respond to expensive drugs

Five things for pharma marketers to know: Thursday, October 5, 2017

Five things for pharma marketers to know: Thursday, October 5, 2017

Cigna will no longer cover OxyContin; the AMA no longer supports price-fixing to lower drug prices; Gottlieb is not in favor of 'right-to-try' laws

How Walgreens overcomes 'consumer complacency' during flu-shot season

How Walgreens overcomes 'consumer complacency' during flu-shot season

In the 2015-16 flu season, more than 145 million doses were distributed by manufacturers, according to the Centers for Disease Control and Prevention, but only 41% of American adults received a vaccine.